BIOTHEUS Trademark

Trademark Overview

On Thursday, April 14, 2022, a trademark application was filed for BIOTHEUS with the United States Patent and Trademark Office. The USPTO has given the BIOTHEUS trademark a serial number of 79344182. The federal status of this trademark filing is REGISTERED as of Tuesday, November 7, 2023. This trademark is owned by Biotheus Inc.. The BIOTHEUS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Medicines used for treating cancers; biological preparations used for treating cancer; anti-cancer pharmaceutical preparations; medicines for human purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases...

Scientific research in the field of medication evaluation; quality control evaluation for others; scientific research in the nature of conducting clinical trials for others; scientific research in the field of antibody; services of medical laboratory
biotheus

General Information

Serial Number79344182
Word MarkBIOTHEUS
Filing DateThursday, April 14, 2022
Status700 - REGISTERED
Status DateTuesday, November 7, 2023
Registration Number7209518
Registration DateTuesday, November 7, 2023
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 22, 2023

Trademark Statements

Description of MarkThe mark consists of the wording "BIOTHEUS" in stylized font above seven Chinese characters positioned horizontally; to the right of the literal element is the stylized depiction of six curving lines of varying sizes surrounding a single shaded dot.
Goods and ServicesMedicines used for treating cancers; biological preparations used for treating cancer; anti-cancer pharmaceutical preparations; medicines for human purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemico-pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemical preparations for pharmaceutical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biological preparations for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biochemicial medicines for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines in the form of injections for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases
Transliteration StatementThe transliteration of the non-Latin characters in the mark is "PU MI SI SHENG WU JI SHU" wherein the word "PU" means "GENERAL," the word "MI" means "METER," the word "SI" means "THIS," and the wording "SHENG WU JI SHU" means "BIOTECHNOLOGY" in English, and the combination of Chinese characters as a whole has no meaning.
Disclaimer with Predetermined TextTHE CHINESE CHARACTERS WHICH TRANSLITERATE TO "SHENG WU JI SHU"
Goods and ServicesScientific research in the field of medication evaluation; quality control evaluation for others; scientific research in the nature of conducting clinical trials for others; scientific research in the field of antibody; services of medical laboratory

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 8, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, July 8, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBiotheus Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressZhuhai, Guangdong 519080
CN
Party NameBiotheus Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressZhuhai, Guangdong 519080
CN
Party NameBiotheus Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressZhuhai, Guangdong 519080
CN

Trademark Events

Event DateEvent Description
Monday, March 4, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, February 8, 2024FINAL DISPOSITION NOTICE SENT TO IB
Thursday, February 8, 2024FINAL DISPOSITION PROCESSED
Wednesday, February 7, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, November 7, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, November 7, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, August 22, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 22, 2023PUBLISHED FOR OPPOSITION
Monday, August 21, 2023NOTIFICATION PROCESSED BY IB
Wednesday, August 2, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, August 2, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 2, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 13, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 13, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 13, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 19, 2023REFUSAL PROCESSED BY IB
Thursday, March 30, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, March 30, 2023REFUSAL PROCESSED BY MPU
Wednesday, February 8, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, February 7, 2023NON-FINAL ACTION WRITTEN
Wednesday, February 1, 2023ASSIGNED TO EXAMINER
Saturday, September 10, 2022NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, July 12, 2022APPLICATION FILING RECEIPT MAILED
Friday, July 8, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 7, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

biotheus diseases system cancer scientific preparations research digestive diabetic circulatory bone